Estes Bram, Sudom Athena, Gong Danyang, Whittington Douglas A, Li Vivian, Mohr Christopher, Li Danqing, Riley Timothy P, Shi Stone D-H, Zhang Jun, Garces Fernando, Wang Zhulun
Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
Department of Therapeutics Discovery, Amgen Research, Amgen Inc., San Francisco, CA 94080, USA.
iScience. 2021 Nov 15;24(12):103447. doi: 10.1016/j.isci.2021.103447. eCollection 2021 Dec 17.
Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3' interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.
双特异性抗体在攻克一些最复杂疾病方面展现出了卓越的临床潜力。然而,在单个细胞中生产双特异性抗体通常需要多条多肽链正确配对以实现所需的组装。这是一个相当大的障碍,阻碍了许多免疫球蛋白G(IgG)样双特异性抗体形式的开发。我们的方法侧重于对带电荷残基进行合理工程改造,以促进不同重链(HC)的链配对。在此,我们运用结构导向的蛋白质设计,对置于抗体(Ab)可结晶片段(Fc)区域的CH3-CH3'界面的电荷对突变(CPM)进行工程改造,以正确引导重链配对。当与我们的稳定无效应功能2(SEFL2.2)技术结合使用时,我们观察到配对效率很高,且表达产量没有显著损失。此外,我们研究了CPM与亲本抗体序列多样性之间的关系,提出了一种合理策略来应用这些工程技术。